Combined therapy with intravenous recombinant tissue plasminogen activator (rt-PA) and edaravone in the acute ischemic stroke patients within 3 hours of onset
Not Applicable
Completed
- Conditions
- Iscemic stroke
- Registration Number
- JPRN-UMIN000002512
- Lead Sponsor
- Department of Stroke Medicine, Kawasaki Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)Diffusion weighted imaging evidence of significant early ischemic change 2)Other exclusion criteria are same as Japan Alteplase Clinical Trial (J-ACT) (stroke 2006;37:1810) 3)exclusion criteria of edaravone administraion mentioned in the package insert. Serume creatinine concentration over 1.5mg/dl
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical improvement Hemorrhagic complication
- Secondary Outcome Measures
Name Time Method